Sen. Angus S. King Jr. Sells Eli Lilly and Company (NYSE:LLY) Shares

Senator Angus S. King Jr. (Independent-Maine) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on March 24th, the Senator disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on February 13th.

Senator Angus S. King Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Autodesk (NASDAQ:ADSK) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of ON (NYSE:ONON) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 2/13/2026.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 12/29/2025.

Eli Lilly and Company Price Performance

NYSE LLY opened at $915.71 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market cap of $865.18 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm’s 50-day simple moving average is $1,013.13 and its two-hundred day simple moving average is $961.39.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the firm earned $5.32 EPS. Eli Lilly and Company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and $1,313 price target, citing the growth potential of Lilly’s new employer access platform for obesity therapies — reinforces buy-side support for LLY’s obesity/GLP‑1 growth story. Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform
• Positive Sentiment: Erste Group nudged its FY2026 EPS estimate slightly higher to $34.40 — small revision but signals analysts are trending upward on modelled profitability from GLP‑1 sales.
• Positive Sentiment: Lilly completed a pediatric pharmacokinetic (PK) study for a next‑gen diabetes candidate — a meaningful clinical milestone that derisks part of the diabetes pipeline and supports future label/market expansion. Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study
• Positive Sentiment: Kroger pharmacies began offering Lilly’s Zepbound KwikPen with support/savings programs — expands retail access for its obesity drug and can help drive adoption and recurring revenue. What Kroger (KR)’s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
• Positive Sentiment: Media and investor commentary (Jim Cramer mentions, fund letters) continue to spotlight Lilly’s GLP‑1 franchises as the primary growth engine, supporting sentiment and retail interest. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: LLY outpaced the broader market intraday (recent reports note a ~1.5% uptick) — reflects short‑term buying tied to the items above rather than new company announcements. Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
• Neutral Sentiment: Valuation debate continues (analyst comparisons with Novo Nordisk, “buy the dip” coverage) — investors are weighing premium multiples against accelerating revenue from obesity drugs. Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity
• Negative Sentiment: Lilly will phase out select insulin products across Europe by 2027 — could trim legacy revenue and requires transition planning; investors may see this as near‑term disruption even if it aligns with strategic product reshaping. Eli Lilly to phase out select insulin products across Europe by 2027

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $1,313.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 21st. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,221.44.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $12,976,634,000. Laurel Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Capital Research Global Investors grew its position in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP increased its position in Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Finally, Cardano Risk Management B.V. lifted its position in Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Senator King

Angus King (independent) is a member of the U.S. Senate from Maine. He assumed office on January 3, 2013. His current term ends on January 3, 2031.

King (independent) ran for re-election to the U.S. Senate to represent Maine. He won in the general election on November 5, 2024.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.